H
H M Lokhorst
Researcher at Utrecht University
Publications - 34
Citations - 2420
H M Lokhorst is an academic researcher from Utrecht University. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 25, co-authored 34 publications receiving 2316 citations. Previous affiliations of H M Lokhorst include VU University Medical Center.
Papers
More filters
Journal ArticleDOI
Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
TL;DR: DLI are effective in a high percentage of patients with relapsed MM after allo-BMT, although it is associated with a high treatment-related toxicity, and patient- adapted therapy consisting of repeated infusions with escalating dose of donor leukocytes until maximum response is achieved may be preferable.
Journal ArticleDOI
Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome
H M Lokhorst,A.V.M.B. Schattenberg,Jeroen J. L. M. Cornelissen,M. H. J. Van Oers,W. E. Fibbe,I. Russell,Niels W.C.J. van de Donk,L. F. Verdonck +7 more
TL;DR: These data confirm the potential and durable graft-versus-myeloma effect of DLI in patients with relapsed MM after AlloSCT and recommend future studies should be aimed at increasing response rates, especially in Patients with chemoresistant disease, and reducing toxicity by limiting GVHD.
Journal ArticleDOI
A gene expression signature for high-risk multiple myeloma.
Rowan Kuiper,Annemiek Broyl,Y de Knegt,M. van Vliet,E H van Beers,B. van der Holt,L el Jarari,George Mulligan,Walter M Gregory,Gareth J. Morgan,H. Goldschmidt,H M Lokhorst,M. van Duin,Pieter Sonneveld +13 more
TL;DR: The EMC-92-gene signature is better or comparable to previously published signatures and contributes to risk assessment in clinical trials and could provide a tool for treatment choices in high-risk MM patients.
Journal ArticleDOI
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
H M Lokhorst,Ingo G.H. Schmidt-Wolf,Pieter Sonneveld,B. van der Holt,Hans Martin,Renee M.Y. Barge,Uta Bertsch,Jana Schlenzka,Gerard M. J. Bos,Sandra Croockewit,Sonja Zweegman,I. Breitkreutz,P. Joosten,Christoph Scheid,M. van Marwijk-Kooy,H Salwender,M. H. J. Van Oers,R. Schaafsma,Ralph Naumann,Harm Sinnige,Igor Wolfgang Blau,Michel Delforge,O. de Weerdt,P. W. Wijermans,S. Wittebol,U. Duersen,Edo Vellenga,H. Goldschmidt +27 more
TL;DR: Patients randomized to TAD had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD and Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD.
Journal ArticleDOI
Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance
Nicolette C. Notermans,H M Lokhorst,H. Franssen,Y. van der Graaf,L. L. Teunissen,Frans G. I. Jennekens,L. H. van den Berg,J.H.J. Wokke +7 more
TL;DR: Short-term treatment with intermittent cyclophosphamide and prednisone may have a long-term favorable effect in patients with demyelinating polyneuropathy associated with MGUS.